Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. 2021

Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
Division of Surgical Oncology, Department of Surgery, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite 410, Miami, FL 33136, USA.

Access to health insurance and curative interventions [surgery/liver-directed-therapy (LDT)] affects survival for early-stage hepatocellular carcinoma (HCC). The aim of this multi-institutional study of high-volume safety-net hospitals (SNHs) and their tertiary-academic-centers (AC) was to identify the impact of type/lack of insurance on survival disparities across hospitals, particularly SNHs whose mission is to minimize insurance related access-to-care barriers for vulnerable populations. Early-stage HCC patients (2012-2014) from the US Safety-Net Collaborative were propensity-score matched by treatment at SNH/AC. Overall survival (OS) was the primary outcome. Multivariable Cox proportional-hazard analysis was performed accounting for sociodemographic/clinical parameters. Among 925 patients, those with no insurance (NI) had decreased curative surgery, compared to those with government insurance (GI) and private insurance [PI, (PI-SNH:60.5% vs. GI-SNH:33.1% vs. NI-SNH:13.6%, p < 0.001)], and decreased median OS (PI-SNH:32.1 vs. GI-SNH:22.8 vs. NI-SNH:9.4 months, p = 0.002). On multivariable regression controlling for sociodemographic/clinical parameters, NI-SNH (HR:2.5, 95% CI:1.3-4.9, p = 0.007) was the only insurance type/hospital system combination with significantly worse OS. NI-SNH patients received less curative treatment than other insurance/hospitals types suggesting that treatment barriers, beyond access-to-care, need to be identified and addressed to achieve survival equity in early-stage HCC for vulnerable populations (NI-SNH).

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D035862 Vulnerable Populations Groups of persons whose range of options is severely limited, who are frequently subjected to COERCION in their DECISION MAKING, or who may be compromised in their ability to give INFORMED CONSENT. Disadvantaged Populations,Patients, Underserved,Populations, Underserved,Sensitive Population Groups,Sensitive Populations,Disadvantaged Population,Patient, Underserved,Population Group, Sensitive,Population, Disadvantaged,Population, Sensitive,Population, Underserved,Population, Vulnerable,Sensitive Population,Sensitive Population Group,Underserved Patient,Underserved Patients,Underserved Population,Underserved Populations,Vulnerable Population
D064876 Safety-net Providers Providers that by mandate or mission organize and deliver a significant level of health care and other health-related services to the uninsured, Medicaid recipients, and other vulnerable patients. Safety-net Clinics,Safety-net Hospitals,Clinic, Safety-net,Clinics, Safety-net,Hospital, Safety-net,Hospitals, Safety-net,Provider, Safety-net,Providers, Safety-net,Safety net Clinics,Safety net Hospitals,Safety net Providers,Safety-net Clinic,Safety-net Hospital,Safety-net Provider

Related Publications

Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
March 2021, Journal of surgical oncology,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
December 2021, Journal of surgical oncology,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
March 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
October 2023, Healthcare (Basel, Switzerland),
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
April 2016, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
December 1994, Faulkner & Gray's medicine & health,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
May 2012, Journal of health care for the poor and underserved,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
January 2016, PloS one,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
December 2010, Zhonghua yi xue za zhi,
Joshua P Kronenfeld, and Emily L Ryon, and David Goldberg, and Rachel M Lee, and Adam Yopp, and Annie Wang, and Ann Y Lee, and Sommer Luu, and Cary Hsu, and Eric Silberfein, and Maria C Russell, and Nipun B Merchant, and Neha Goel
November 2014, Medical care,
Copied contents to your clipboard!